We cooperate with the industrial partners in the field of quality control of dairy and probiotic products and in the development of new products. In recent years, many efforts were devoted to the development of modern methods of quality control of probiotic products and to the searching and testing of new strains - candidates for industrial probiotics. The most extensive cooperation is established with the dairy and pharmaceutical industries.
The researchers of the Institute of Dairy and Probiotics have been collaborating with the biotech company Arhel d.o.o.
since 2017, when we launched the joint project LIFE for Acid Whey
"Reuse of waste acid whey for extraction of high added value bioactive proteins", funded by the European funding mechanism LIFE Environment. As part of the aforementioned project, we researched lactoferrin protein from acid whey, a by-product of the dairy industry, and looked for diverse ways to further process acid whey. We strengthened our cooperation through joint activities in the LAKTIKA
project "Fractionation and processing of whey proteins and exploitation of the residue for the formation of new functional foods and food supplements" (Operational Program for the implementation of the European Cohesion Policy in the period 2014-2020). We have developed advanced technological methods for the isolation and addition of individual whey proteins and proposed new solutions for the use of whey residues for innovative food supplements and functional food supplements. The results achieved contribute to the establishment of new breakthrough technological processes for obtaining innovative products with high added value and increasing the competitiveness of the dairy industry. Through further collaboration, we also aim to strengthen the role of the Biotechnology Faculty in solving environmental and technological challenges and improving the competitiveness of the food industry.
Together with Mlekarna Celeia
dairy and Clinres
company we tested in a clinical study the efficacy of a fermented synbiotic product in adults with irritable bowel syndrome (IBS), and in cooperation with the company Medis
, the effectiveness of a pharmaceutical preparation containing two probiotic strains of Lactobacillus fermentum
and Bifidobacterium animalis
derived from the intestinal mucosa, also in adults with IBS. In cooperation with Medis
, we developed a new dietary supplement with bioactive peptides for preventive treatments of subjects with the risk of cardiovascular diseases, which has been shown effective in a clinical study in subjects with increased blood pressure. With the dairy Celeia
we were involved also in the development and formulation of a new whey-based product intended for the active population (recreational athletes). The majority of these studies took place in the frame of The competence centre for Biotechnological Development and Innovation (KC-BRIN
). In cooperation with pharmaceutical company we monitor the quality and safety of their probiotic OTC product for over a decade. We also developed together a specific culture-independent method for determination of the viability of probiotic bacteria in their product based on molecular biological method PCR. It is worth mentioning also the determination of contamination of raw materials (for probiotic products), sterility testing of laboratory consumables and offer of our own isolates of lactic acid bacteria and bifidobacteria with the properties interesting for industrial strains (probiotics, cultures for fermented products .. ...) stored in our culture collection of microorganisms.